Clinical Trial Update: Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing SHINGRIX vaccine response in chronic lymphocytic leukemia patients, including those treated with BTK inhibitors; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates | Phase 2 | Status: COMPLETED | Results posted: 2021-12-15